RaySearch Laboratories Past Earnings Performance
Past criteria checks 5/6
RaySearch Laboratories has been growing earnings at an average annual rate of 14.7%, while the Healthcare Services industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 9.2% per year. RaySearch Laboratories's return on equity is 19.7%, and it has net margins of 13.4%.
Key information
14.7%
Earnings growth rate
14.7%
EPS growth rate
| Healthcare Services Industry Growth | 12.5% |
| Revenue growth rate | 9.2% |
| Return on equity | 19.7% |
| Net Margin | 13.4% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RaySearch Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,129 | 151 | 565 | 260 |
| 31 Mar 24 | 1,049 | 101 | 560 | 249 |
| 31 Dec 23 | 1,022 | 82 | 558 | 238 |
| 30 Sep 23 | 987 | 64 | 540 | 229 |
| 30 Jun 23 | 945 | 53 | 529 | 230 |
| 31 Mar 23 | 866 | 22 | 498 | 232 |
| 31 Dec 22 | 844 | 24 | 481 | 239 |
| 30 Sep 22 | 768 | -6 | 477 | 243 |
| 30 Jun 22 | 693 | -38 | 455 | 241 |
| 31 Mar 22 | 688 | -35 | 442 | 238 |
| 31 Dec 21 | 642 | -47 | 422 | 233 |
| 30 Sep 21 | 613 | -46 | 390 | 218 |
| 30 Jun 21 | 596 | -50 | 376 | 204 |
| 31 Mar 21 | 605 | -42 | 368 | 194 |
| 31 Dec 20 | 652 | -9 | 398 | 185 |
| 30 Sep 20 | 726 | 24 | 421 | 183 |
| 30 Jun 20 | 751 | 43 | 454 | 181 |
| 31 Mar 20 | 777 | 74 | 472 | 180 |
| 31 Dec 19 | 742 | 50 | 446 | 175 |
| 30 Sep 19 | 727 | 64 | 438 | 168 |
| 30 Jun 19 | 733 | 85 | 405 | 159 |
| 31 Mar 19 | 684 | 84 | 384 | 152 |
| 31 Dec 18 | 627 | 79 | 354 | 148 |
| 30 Sep 18 | 613 | 118 | 313 | 135 |
| 30 Jun 18 | 574 | 104 | 297 | 124 |
| 31 Mar 18 | 575 | 103 | 278 | 115 |
| 31 Dec 17 | 585 | 118 | 268 | 104 |
| 30 Sep 17 | 571 | 121 | 252 | 102 |
| 30 Jun 17 | 586 | 151 | 247 | 100 |
| 31 Mar 17 | 563 | 160 | 233 | 98 |
| 31 Dec 16 | 531 | 151 | 223 | 93 |
| 30 Sep 16 | 472 | 109 | 218 | 89 |
| 30 Jun 16 | 447 | 94 | 203 | 92 |
| 31 Mar 16 | 405 | 63 | 193 | 96 |
| 31 Dec 15 | 398 | 70 | 182 | 102 |
| 30 Sep 15 | 373 | 78 | 158 | 105 |
| 30 Jun 15 | 344 | 76 | 140 | 100 |
| 31 Mar 15 | 319 | 79 | 121 | 96 |
| 31 Dec 14 | 285 | 60 | 109 | 95 |
| 30 Sep 14 | 268 | 24 | 141 | 96 |
| 30 Jun 14 | 235 | -4 | 138 | 96 |
| 31 Mar 14 | 211 | -20 | 136 | 94 |
| 31 Dec 13 | 204 | -21 | 133 | 91 |
| 30 Sep 13 | 191 | -1 | 97 | 85 |
Quality Earnings: 0GRZ has high quality earnings.
Growing Profit Margin: 0GRZ's current net profit margins (13.4%) are higher than last year (5.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0GRZ's earnings have grown by 14.7% per year over the past 5 years.
Accelerating Growth: 0GRZ's earnings growth over the past year (187%) exceeds its 5-year average (14.7% per year).
Earnings vs Industry: 0GRZ earnings growth over the past year (187%) exceeded the Healthcare Services industry 9.3%.
Return on Equity
High ROE: 0GRZ's Return on Equity (19.7%) is considered low.